1. Pink Sheet
  2. >>Vaccines

Universal Flu Vaccine Is Still Several Years Away, Fauci Says

 
• By Michael Cipriano

Developing a universal flu vaccine will be iterative process, National Institute of Allergy and Infectious Diseases Anthony Fauci says.

Vaccination

A universal flu vaccine is the best solution to boost the substandard efficacy of the current vaccines for the disease, but it will take several years just for the candidates under clinical development to demonstrate they can induce immunity against a single strain, National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci says.

Speaking at the National Press Club last month on the heels of a northern hemisphere flu season with high levels of the illness, Fauci explained that developing a universal vaccine...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.

EMA Says Digital Transformation A ‘Fundamental Shift’ In Meeting Regulatory Challenges

 
• By Eliza Slawther

Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.